Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Niagen Bioscience (NAGE) Other Operating Expenses: 2010-2025

Historic Other Operating Expenses for Niagen Bioscience (NAGE) over the last 14 years, with Sep 2025 value amounting to $8.8 million.

  • Niagen Bioscience's Other Operating Expenses rose 24.47% to $8.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $33.8 million, marking a year-over-year increase of 23.96%. This contributed to the annual value of $29.5 million for FY2024, which is 11.46% up from last year.
  • As of Q3 2025, Niagen Bioscience's Other Operating Expenses stood at $8.8 million, which was up 6.84% from $8.2 million recorded in Q2 2025.
  • In the past 5 years, Niagen Bioscience's Other Operating Expenses ranged from a high of $8.8 million in Q3 2025 and a low of $5.9 million during Q3 2022.
  • In the last 3 years, Niagen Bioscience's Other Operating Expenses had a median value of $7.0 million in 2024 and averaged $7.4 million.
  • Per our database at Business Quant, Niagen Bioscience's Other Operating Expenses spiked by 40.72% in 2021 and then dropped by 28.40% in 2022.
  • Niagen Bioscience's Other Operating Expenses (Quarterly) stood at $8.6 million in 2021, then declined by 28.40% to $6.2 million in 2022, then climbed by 5.38% to $6.5 million in 2023, then skyrocketed by 33.68% to $8.7 million in 2024, then increased by 24.47% to $8.8 million in 2025.
  • Its last three reported values are $8.8 million in Q3 2025, $8.2 million for Q2 2025, and $8.1 million during Q1 2025.